Search results

518 results

View results as:
Number of results to display per page
Book
1 online resource : text file, PDF
  • Prologue Jose L. Arias Key Aspects in Nanotechnology and Drug Delivery Jose L. Arias Drug Delivery and Release from Polymeric Nanomaterials Cornelia Vasile, Ana Maria Oprea, Manuela Tatiana Nistor and Anca-Maria Cojocariu Nano-Sized Polymeric Drug Carrier Systems Cornelia Vasile, Manuela Tatiana Nistor and Anca-Maria Cojocariu Reversible Cross-Linked Polymeric Nanoplatform in Drug Delivery Yuanpei Li, Kai Xiao and Kit S. Lam Cyclodextrins in Drug Delivery Nazli Erdogar and Erem Bilensoy Drug Delivery Systems Based on Tyrosine-derived Nanospheres (TyroSpheresTM) Zheng Zhang, Tannaz Ramezanli, Pei-Chin Tsai and Bozena B. Michniak-Kohn Carbon Nanotubes for Drug Delivery Applications Yitzhak Rosen and Pablo Gurman Metallic Nanoparticulate Drug Delivery Systems Varsha B. Pokharkar, Vividha V. Dhapte and Shivajirao S. Kadam Porous Silica Nanoparticles for Drug Delivery and Controlled Release Xiaoxing Sun and Brian G. Trewyn Iron Oxides in Drug Delivery Fahima Dilnawaz and Sanjeeb Kumar Sahoo Nanoengineered Magnetic Field-Induced Targeted Drug Delivery System with Stimuli Responsive Release R. Devesh K. Misra.
  • (source: Nielsen Book Data)
Pharmacotherapy is often limited by the inefficient activity and severe toxicity of drug molecules. Nanotechnology offers a revolutionary and definitive approach for the efficient delivery of drug molecules to non-healthy tissues and cells. This first volume of a series of two volumes analyzes the basics in the development of drug-loaded nanoplatforms, the so-called nanomedicines. Special attention is given to physicochemical engineering, pharmacokinetics, biocompatibility and biodegradability, representative nanoplatforms (based on lipids, polymers, cyclodextrins, metals, carbon, silica, iron oxides, etc.), and advanced nano-engineering strategies for passive, ligand-mediated, and/or stimuli-sensitive drug delivery and release.
(source: Nielsen Book Data)
  • Prologue Jose L. Arias Key Aspects in Nanotechnology and Drug Delivery Jose L. Arias Drug Delivery and Release from Polymeric Nanomaterials Cornelia Vasile, Ana Maria Oprea, Manuela Tatiana Nistor and Anca-Maria Cojocariu Nano-Sized Polymeric Drug Carrier Systems Cornelia Vasile, Manuela Tatiana Nistor and Anca-Maria Cojocariu Reversible Cross-Linked Polymeric Nanoplatform in Drug Delivery Yuanpei Li, Kai Xiao and Kit S. Lam Cyclodextrins in Drug Delivery Nazli Erdogar and Erem Bilensoy Drug Delivery Systems Based on Tyrosine-derived Nanospheres (TyroSpheresTM) Zheng Zhang, Tannaz Ramezanli, Pei-Chin Tsai and Bozena B. Michniak-Kohn Carbon Nanotubes for Drug Delivery Applications Yitzhak Rosen and Pablo Gurman Metallic Nanoparticulate Drug Delivery Systems Varsha B. Pokharkar, Vividha V. Dhapte and Shivajirao S. Kadam Porous Silica Nanoparticles for Drug Delivery and Controlled Release Xiaoxing Sun and Brian G. Trewyn Iron Oxides in Drug Delivery Fahima Dilnawaz and Sanjeeb Kumar Sahoo Nanoengineered Magnetic Field-Induced Targeted Drug Delivery System with Stimuli Responsive Release R. Devesh K. Misra.
  • (source: Nielsen Book Data)
Pharmacotherapy is often limited by the inefficient activity and severe toxicity of drug molecules. Nanotechnology offers a revolutionary and definitive approach for the efficient delivery of drug molecules to non-healthy tissues and cells. This first volume of a series of two volumes analyzes the basics in the development of drug-loaded nanoplatforms, the so-called nanomedicines. Special attention is given to physicochemical engineering, pharmacokinetics, biocompatibility and biodegradability, representative nanoplatforms (based on lipids, polymers, cyclodextrins, metals, carbon, silica, iron oxides, etc.), and advanced nano-engineering strategies for passive, ligand-mediated, and/or stimuli-sensitive drug delivery and release.
(source: Nielsen Book Data)
Book
1 online resource.
"This book details many of the problems and successes of peptides as potential drugs"--Provided by publisher.
"This book details many of the problems and successes of peptides as potential drugs"--Provided by publisher.
Book
1 online resource.
  • Basic ideas in clinical trial design
  • Sampling and inferential statistics
  • Confidence intervals and p-values
  • Tests for simple treatment comparisons
  • Adjusting the analysis
  • Regression and analysis of covariance
  • Intention-to-treat and analysis sets
  • Power and sample size
  • Statistical significance and clinical importance
  • Multiple testing
  • Non-parametric and related methods
  • Equivalence and non-inferiority
  • The analysis of survival data
  • Interim analysis and data monitoring committees
  • Bayesian statistics
  • Adaptive designs
  • Observational studies
  • Meta-analysis
  • Methods for the safety analysis and safety monitoring
  • Diagnosis
  • The role of statistics and statisticians.
  • Basic ideas in clinical trial design
  • Sampling and inferential statistics
  • Confidence intervals and p-values
  • Tests for simple treatment comparisons
  • Adjusting the analysis
  • Regression and analysis of covariance
  • Intention-to-treat and analysis sets
  • Power and sample size
  • Statistical significance and clinical importance
  • Multiple testing
  • Non-parametric and related methods
  • Equivalence and non-inferiority
  • The analysis of survival data
  • Interim analysis and data monitoring committees
  • Bayesian statistics
  • Adaptive designs
  • Observational studies
  • Meta-analysis
  • Methods for the safety analysis and safety monitoring
  • Diagnosis
  • The role of statistics and statisticians.
Book
1 online resource
  • Part I: General Aspects. Serendipitous Target-Based Drug Discoveries / János Fischer, David P Rotella
  • Drug Discoveries and Molecular Mechanism of Action / David C Swinney
  • Part II: Drug Class. Insulin Analogs - Improving the Therapy of Diabetes / John M Beals
  • Part III: Case Histories. The Discovery of Stendra (Avanafil) for the Treatment of Erectile Dysfunction / Koichiro Yamada, Toshiaki Sakamoto, Kenji Omori, Kohei Kikkawa
  • Dapagliflozin, A Selective SGLT2 Inhibitor for Treatment of Diabetes / William N Washburn
  • Elvitegravir, A New HIV-1 Integrase Inhibitor for Antiretroviral Therapy / Hisashi Shinkai
  • Discovery of Linagliptin for the Treatment of Type 2 Diabetes Mellitus / Matthias Eckhardt, Thomas Klein, Herbert Nar, Sandra Thiemann
  • The Discovery of Alimta (Pemetrexed) / Edward C Taylor
  • Perampanel: A Novel, Noncompetitive AMPA Receptor Antagonist for the Treatment of Epilepsy / Shigeki Hibi
  • Discovery and Development of Telaprevir (Incivek): A Protease Inhibitor to Treat Hepatitis C Infection / Bhisetti G Rao, Mark Murcko, Mark J Tebbe, Ann D Kwong
  • Antibody-Drug Conjugates: Design and Development of Trastuzumab Emtansine (T-DM1) / Sandhya Girish, Gail D Lewis Phillips, Fredric S Jacobson, Jagath R Junutula, Ellie Guardino.
  • Part I: General Aspects. Serendipitous Target-Based Drug Discoveries / János Fischer, David P Rotella
  • Drug Discoveries and Molecular Mechanism of Action / David C Swinney
  • Part II: Drug Class. Insulin Analogs - Improving the Therapy of Diabetes / John M Beals
  • Part III: Case Histories. The Discovery of Stendra (Avanafil) for the Treatment of Erectile Dysfunction / Koichiro Yamada, Toshiaki Sakamoto, Kenji Omori, Kohei Kikkawa
  • Dapagliflozin, A Selective SGLT2 Inhibitor for Treatment of Diabetes / William N Washburn
  • Elvitegravir, A New HIV-1 Integrase Inhibitor for Antiretroviral Therapy / Hisashi Shinkai
  • Discovery of Linagliptin for the Treatment of Type 2 Diabetes Mellitus / Matthias Eckhardt, Thomas Klein, Herbert Nar, Sandra Thiemann
  • The Discovery of Alimta (Pemetrexed) / Edward C Taylor
  • Perampanel: A Novel, Noncompetitive AMPA Receptor Antagonist for the Treatment of Epilepsy / Shigeki Hibi
  • Discovery and Development of Telaprevir (Incivek): A Protease Inhibitor to Treat Hepatitis C Infection / Bhisetti G Rao, Mark Murcko, Mark J Tebbe, Ann D Kwong
  • Antibody-Drug Conjugates: Design and Development of Trastuzumab Emtansine (T-DM1) / Sandhya Girish, Gail D Lewis Phillips, Fredric S Jacobson, Jagath R Junutula, Ellie Guardino.
Book
1 online resource (xiii, 550 pages) : illustrations (some color).
  • 1 Hybrid QM/MM Methods: Treating Electronic Phenomena in Very Large Molecular Systems
  • 2 Structure, Thermodynamics and Energetics of Drug-DNA Interactions: Computer Modeling and Experiment
  • 3 Formation of DNA Lesions, Its Prevention and Repair
  • 4 DNA dependent DNA Polymerases as Targets for Low-Weight Molecular Inhibitors: State of Art and Prospects of Rational Design
  • 5 Molecular structures, relative stability, and proton affinities of nucleotides: Broad view and novel findings
  • 6 Quantum Chemical Approaches in Modeling the Structure of Quadruplex DNA and Its Interaction with Metal Ions and Small Molecules
  • 7 Density Functional Theory Calculations of Enzyme-Inhibitor Interactions in Medicinal Chemistry and Drug Design
  • 8 Molecular Dynamics Simulations of Lipid Bilayers with Incorporated Peptides
  • 9 Polyphenol Glycosides as Potential Remedies in Kidney Stones Therapy. Experimental Research Supported by Computational Studies
  • 10 Quantum-Chemical Investigation of Epoxidic Compounds Transformation. Application for In Vitro and In Vivo Processes Modeling
  • 11 Computational Toxicology in Drug Discovery: opportunities and limitations
  • 12 Consensus Drug Design Using it Microcosm
  • 13 Continuous Molecular Fields Approach Applied to Structure-Activity Modeling
  • 14 Quantitative Structure-Pharmacokinetic Relationships of Drugs within the Framework of Biopharmaceutics Classification System by Using Simplex Representation of Molecular Structure
  • 15 (How to) Profit from Molecular Dynamics-based Ensemble Docking
  • 16 Cheminformatics on Crossroad of Eras.
The current volume provides both fundamental and detailed information about the computational and computational-experimental studies which improve our knowledge of how leaving matter functions. It also covers research areas related to structures and properties of drugs (including the calculation and the design of new ones), and the development of completely new ways of treating numerical diseases. Whenever it is possible, the interplay between theory and experiment is emphasized. The book features computational techniques such as quantum-chemical and molecular dynamic approaches supplemented by a discussion on quantitative structure?activity relationships. The initial chapters describe the state-of-the art computational approaches for molecular biology, molecular pharmacy, and molecular medicine performed with the use of pure quantum-chemical techniques. The central part of the book illustrates the status of computational techniques that utilize hybrid, so called QM/MM approximations. In addition, the results of the QSAR studies, which now are the most popular in predicting drugs? efficiency, are discussed. The last chapter reveals the current state of chemoinformatics and discusses new problems and experimental perspectives related to both chemical and biological characteristics of molecules.
  • 1 Hybrid QM/MM Methods: Treating Electronic Phenomena in Very Large Molecular Systems
  • 2 Structure, Thermodynamics and Energetics of Drug-DNA Interactions: Computer Modeling and Experiment
  • 3 Formation of DNA Lesions, Its Prevention and Repair
  • 4 DNA dependent DNA Polymerases as Targets for Low-Weight Molecular Inhibitors: State of Art and Prospects of Rational Design
  • 5 Molecular structures, relative stability, and proton affinities of nucleotides: Broad view and novel findings
  • 6 Quantum Chemical Approaches in Modeling the Structure of Quadruplex DNA and Its Interaction with Metal Ions and Small Molecules
  • 7 Density Functional Theory Calculations of Enzyme-Inhibitor Interactions in Medicinal Chemistry and Drug Design
  • 8 Molecular Dynamics Simulations of Lipid Bilayers with Incorporated Peptides
  • 9 Polyphenol Glycosides as Potential Remedies in Kidney Stones Therapy. Experimental Research Supported by Computational Studies
  • 10 Quantum-Chemical Investigation of Epoxidic Compounds Transformation. Application for In Vitro and In Vivo Processes Modeling
  • 11 Computational Toxicology in Drug Discovery: opportunities and limitations
  • 12 Consensus Drug Design Using it Microcosm
  • 13 Continuous Molecular Fields Approach Applied to Structure-Activity Modeling
  • 14 Quantitative Structure-Pharmacokinetic Relationships of Drugs within the Framework of Biopharmaceutics Classification System by Using Simplex Representation of Molecular Structure
  • 15 (How to) Profit from Molecular Dynamics-based Ensemble Docking
  • 16 Cheminformatics on Crossroad of Eras.
The current volume provides both fundamental and detailed information about the computational and computational-experimental studies which improve our knowledge of how leaving matter functions. It also covers research areas related to structures and properties of drugs (including the calculation and the design of new ones), and the development of completely new ways of treating numerical diseases. Whenever it is possible, the interplay between theory and experiment is emphasized. The book features computational techniques such as quantum-chemical and molecular dynamic approaches supplemented by a discussion on quantitative structure?activity relationships. The initial chapters describe the state-of-the art computational approaches for molecular biology, molecular pharmacy, and molecular medicine performed with the use of pure quantum-chemical techniques. The central part of the book illustrates the status of computational techniques that utilize hybrid, so called QM/MM approximations. In addition, the results of the QSAR studies, which now are the most popular in predicting drugs? efficiency, are discussed. The last chapter reveals the current state of chemoinformatics and discusses new problems and experimental perspectives related to both chemical and biological characteristics of molecules.

6. Chemistry of drugs [2014]

Book
x, 260 p. : ill. ; 24 cm.
Chemistry & ChemEng Library (Swain)
Status of items at Chemistry & ChemEng Library (Swain)
Chemistry & ChemEng Library (Swain) Status
Stacks
RS403 .B27 2014 Unknown
Book
online resource (xii, 252 pages) : illustrations (some color)
This book focuses on applications of compound library design and virtual screening to expand the bioactive chemical space, to target hopping of chemotypes to identify synergies within related drug discovery projects or to repurpose known drugs, to propose mechanism of action of compounds, or to identify off-target effects by cross-reactivity analysis. Both ligand-based and structure-based in silico approaches, as reviewed in this book, play important roles for all these applications. Computational chemogenomics is expected to increase the quality and productivity of drug discovery and lead.
This book focuses on applications of compound library design and virtual screening to expand the bioactive chemical space, to target hopping of chemotypes to identify synergies within related drug discovery projects or to repurpose known drugs, to propose mechanism of action of compounds, or to identify off-target effects by cross-reactivity analysis. Both ligand-based and structure-based in silico approaches, as reviewed in this book, play important roles for all these applications. Computational chemogenomics is expected to increase the quality and productivity of drug discovery and lead.
Medical Library (Lane)
Status of items at Medical Library (Lane)
Medical Library (Lane) Status
Check Medical Library (Lane) catalog for status
CRCNETBASE Unknown
Book
1 online resource (xxiv, 553 pages)
Systematically examining current methods and strategies, this ready reference covers a wide range of molecular structures, from organic-chemical drugs to peptides, proteins and nucleic acids, in line with emerging new drug classes derived from biomacromolecules. A leader in the field and one of the pioneers of this young discipline has assembled here the most prominent experts from across the world to provide first-hand knowledge. While most of their methods and examples come from the area of pharmaceutical discovery and development, the approaches are equally applicable for molecular probes and diagnostics, pesticides, and any other molecule designed to interact with a biological system. Hundreds of images and screenshots, many of them in full color, illustrate the examples and method descriptions. With its broad and balanced coverage, this will be the first-stop resource for medicinal chemists, biochemists and biotechnologists for many years to come.
(source: Nielsen Book Data)
Systematically examining current methods and strategies, this ready reference covers a wide range of molecular structures, from organic-chemical drugs to peptides, proteins and nucleic acids, in line with emerging new drug classes derived from biomacromolecules. A leader in the field and one of the pioneers of this young discipline has assembled here the most prominent experts from across the world to provide first-hand knowledge. While most of their methods and examples come from the area of pharmaceutical discovery and development, the approaches are equally applicable for molecular probes and diagnostics, pesticides, and any other molecule designed to interact with a biological system. Hundreds of images and screenshots, many of them in full color, illustrate the examples and method descriptions. With its broad and balanced coverage, this will be the first-stop resource for medicinal chemists, biochemists and biotechnologists for many years to come.
(source: Nielsen Book Data)
Book
1 online resource (xi, 511 pages) : illustrations (some color).
Book
1 online resource (366 pages) : illustrations.
  • Contributors vii Preface ix Part A -Enzymes essential workhorses inpharmaceutical research 1 1 Assay Technologies for Proteases 3 Anuradha Roy, Gerald H. Lushington, James McGee, and RathnamChaguturu 2 Discovery and Development of Isozyme-Selective InhibitorsInvolved in Lipid Metabolism 55 Taichi Ohshiro and Hiroshi Tomoda 3 Covalent Enzyme Inhibition in Drug Discovery and Development81 Shujaath Mehdi 4 Preclinomics: Enzyme Assays and Rodent Models for Metabolicdiseases 131 Wu-Kuang Yeh and Richard G. Peterson Part B -Enzymes indispensable tools forimproving druggability 163 5 Enzymes and Targeted Activation of Prodrugs 165 Yanhui Yang, Yu Chen, Herve Aloysius, Daigo Inoyama, and LongqinHu 6 Evolution of an Orally Active Prodrug of Gemcitabine 237 James R. McCarthy 7 Enzymatically Activated Phosphate and Phosphonate Prodrugs253 Ivan S. Krylov and Charles E. McKenna Part C E nzymes powerful weapons for correctingNature s errors 301 8 Treatment Options for Mucopolysaccharidosis Type II(Hunter s Syndrome) 303 Michael Beck 9 Enzyme Replacement Therapy for Fabry Disease 321 Ley Nadine Lacbawan, Wei Zheng, and Ozlem Goker-Alpan 10 Methods and Principles of Pancreatic Function Tests 335 Henrike von Schassen, Jutta Keller, and Peter Layer Index 341.
  • (source: Nielsen Book Data)
Highlighting the critical importance of enzymes in pharmaceutical and biotechnology research, Enzyme Technologies presents thorough discussions on chemical biology of enzymes, redesigning binding and catalytic specificities of enzymes, and applications of enzymes to biotechnology research in the post-genomic era. This timely review presents researchers, students, and faculty with expert reviews of recent progress in comprehending molecular mechanisms of biosynthetic and biocatalytic processes as well as how to utilize that knowledge for practical applications.
(source: Nielsen Book Data)
  • Contributors vii Preface ix Part A -Enzymes essential workhorses inpharmaceutical research 1 1 Assay Technologies for Proteases 3 Anuradha Roy, Gerald H. Lushington, James McGee, and RathnamChaguturu 2 Discovery and Development of Isozyme-Selective InhibitorsInvolved in Lipid Metabolism 55 Taichi Ohshiro and Hiroshi Tomoda 3 Covalent Enzyme Inhibition in Drug Discovery and Development81 Shujaath Mehdi 4 Preclinomics: Enzyme Assays and Rodent Models for Metabolicdiseases 131 Wu-Kuang Yeh and Richard G. Peterson Part B -Enzymes indispensable tools forimproving druggability 163 5 Enzymes and Targeted Activation of Prodrugs 165 Yanhui Yang, Yu Chen, Herve Aloysius, Daigo Inoyama, and LongqinHu 6 Evolution of an Orally Active Prodrug of Gemcitabine 237 James R. McCarthy 7 Enzymatically Activated Phosphate and Phosphonate Prodrugs253 Ivan S. Krylov and Charles E. McKenna Part C E nzymes powerful weapons for correctingNature s errors 301 8 Treatment Options for Mucopolysaccharidosis Type II(Hunter s Syndrome) 303 Michael Beck 9 Enzyme Replacement Therapy for Fabry Disease 321 Ley Nadine Lacbawan, Wei Zheng, and Ozlem Goker-Alpan 10 Methods and Principles of Pancreatic Function Tests 335 Henrike von Schassen, Jutta Keller, and Peter Layer Index 341.
  • (source: Nielsen Book Data)
Highlighting the critical importance of enzymes in pharmaceutical and biotechnology research, Enzyme Technologies presents thorough discussions on chemical biology of enzymes, redesigning binding and catalytic specificities of enzymes, and applications of enzymes to biotechnology research in the post-genomic era. This timely review presents researchers, students, and faculty with expert reviews of recent progress in comprehending molecular mechanisms of biosynthetic and biocatalytic processes as well as how to utilize that knowledge for practical applications.
(source: Nielsen Book Data)
Book
1 online resource.
Increasing the potency of therapeutic compounds, while limiting side-effects, is a common goal in medicinal chemistry. Ligands that effectively bind metal ions and also include specific features to enhance targeting, reporting, and overall efficacy are driving innovation in areas of disease diagnosis and therapy. Ligand Design in Medicinal Inorganic Chemistry presents the state-of-the-art in ligand design for medicinal inorganic chemistry applications. Each individual chapter describes and explores the application of compounds that either target a disease site, or are activated by a disease-specific biological process. Ligand design is discussed in the following areas: * Platinum, Ruthenium, and Gold-containing anticancer agents * Emissive metal-based optical probes * Metal-based antimalarial agents * Metal overload disorders * Modulation of metal-protein interactions in neurodegenerative diseases * Photoactivatable metal complexes and their use in biology and medicine * Radiodiagnostic agents and Magnetic Resonance Imaging (MRI) agents * Carbohydrate-containing ligands and Schiff-base ligands in Medicinal Inorganic Chemistry * Metalloprotein inhibitors Ligand Design in Medicinal Inorganic Chemistry provides graduate students, industrial chemists and academic researchers with a launching pad for new research in medicinal chemistry.
(source: Nielsen Book Data)
Increasing the potency of therapeutic compounds, while limiting side-effects, is a common goal in medicinal chemistry. Ligands that effectively bind metal ions and also include specific features to enhance targeting, reporting, and overall efficacy are driving innovation in areas of disease diagnosis and therapy. Ligand Design in Medicinal Inorganic Chemistry presents the state-of-the-art in ligand design for medicinal inorganic chemistry applications. Each individual chapter describes and explores the application of compounds that either target a disease site, or are activated by a disease-specific biological process. Ligand design is discussed in the following areas: * Platinum, Ruthenium, and Gold-containing anticancer agents * Emissive metal-based optical probes * Metal-based antimalarial agents * Metal overload disorders * Modulation of metal-protein interactions in neurodegenerative diseases * Photoactivatable metal complexes and their use in biology and medicine * Radiodiagnostic agents and Magnetic Resonance Imaging (MRI) agents * Carbohydrate-containing ligands and Schiff-base ligands in Medicinal Inorganic Chemistry * Metalloprotein inhibitors Ligand Design in Medicinal Inorganic Chemistry provides graduate students, industrial chemists and academic researchers with a launching pad for new research in medicinal chemistry.
(source: Nielsen Book Data)
Book
1 online resource (viii, 202 pages) : illustrations (some color)
Book
1 online resource.
  • Introduction
  • Lead discovery and lead modification
  • Receptors
  • Enzymes
  • Enzyme inhibition and inactivation
  • Dna-interactive agents
  • Drug resistance and drug synergism
  • Drug metabolism
  • Prodrugs and drug delivery systems.
The Organic Chemistry of Drug Design and Drug Action, Third Edition, represents a unique approach to medicinal chemistry based on physical organic chemical principles and reaction mechanisms that rationalize drug action, which allows the reader to extrapolate those core principles and mechanisms to many related classes of drug molecules. This new edition reflects significant changes in the process of drug design over the last decade. It preserves the successful approach of the previous editions while including significant changes in format and coverage. New to this edition: * Updates to all chapters, including new examples and references* Chapter 1 (Introduction): Completely rewritten and expanded as an overview of topics discussed in detail throughout the book* Chapter 2 (Lead Discovery and Lead Modification): Sections on sources of compounds for screening including library collections, virtual screening, and computational methods, as well as hit-to-lead and scaffold hopping; expanded sections on sources of lead compounds, fragment-based lead discovery, and molecular graphics; and deemphasized solid-phase synthesis and combinatorial chemistry* Chapter 3 (Receptors): Drug-receptor interactions, cation-? and halogen bonding; atropisomers; case history of the insomnia drug suvorexant* Chapter 4 (Enzymes): Expanded sections on enzyme catalysis in drug discovery and enzyme synthesis* Chapter 5 (Enzyme Inhibition and Inactivation): New case histories: * for competitive inhibition, the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib and Abelson kinase inhibitor, imatinib* for transition state analogue inhibition, the purine nucleoside phosphorylase inhibitors, forodesine and DADMe-ImmH, as well as the mechanism of the multisubstrate analog inhibitor isoniazid* for slow, tight-binding inhibition, the dipeptidyl peptidase-4 inhibitor, saxagliptin* Chapter 7 (Drug Resistance and Drug Synergism): This new chapter includes topics taken from two chapters in the previous edition, with many new examples* Chapter 8 (Drug Metabolism): Discussions of toxicophores and reactive metabolites* Chapter 9 (Prodrugs and Drug Delivery Systems): Discussion of antibody-drug conjugates.
(source: Nielsen Book Data)
  • Introduction
  • Lead discovery and lead modification
  • Receptors
  • Enzymes
  • Enzyme inhibition and inactivation
  • Dna-interactive agents
  • Drug resistance and drug synergism
  • Drug metabolism
  • Prodrugs and drug delivery systems.
The Organic Chemistry of Drug Design and Drug Action, Third Edition, represents a unique approach to medicinal chemistry based on physical organic chemical principles and reaction mechanisms that rationalize drug action, which allows the reader to extrapolate those core principles and mechanisms to many related classes of drug molecules. This new edition reflects significant changes in the process of drug design over the last decade. It preserves the successful approach of the previous editions while including significant changes in format and coverage. New to this edition: * Updates to all chapters, including new examples and references* Chapter 1 (Introduction): Completely rewritten and expanded as an overview of topics discussed in detail throughout the book* Chapter 2 (Lead Discovery and Lead Modification): Sections on sources of compounds for screening including library collections, virtual screening, and computational methods, as well as hit-to-lead and scaffold hopping; expanded sections on sources of lead compounds, fragment-based lead discovery, and molecular graphics; and deemphasized solid-phase synthesis and combinatorial chemistry* Chapter 3 (Receptors): Drug-receptor interactions, cation-? and halogen bonding; atropisomers; case history of the insomnia drug suvorexant* Chapter 4 (Enzymes): Expanded sections on enzyme catalysis in drug discovery and enzyme synthesis* Chapter 5 (Enzyme Inhibition and Inactivation): New case histories: * for competitive inhibition, the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib and Abelson kinase inhibitor, imatinib* for transition state analogue inhibition, the purine nucleoside phosphorylase inhibitors, forodesine and DADMe-ImmH, as well as the mechanism of the multisubstrate analog inhibitor isoniazid* for slow, tight-binding inhibition, the dipeptidyl peptidase-4 inhibitor, saxagliptin* Chapter 7 (Drug Resistance and Drug Synergism): This new chapter includes topics taken from two chapters in the previous edition, with many new examples* Chapter 8 (Drug Metabolism): Discussions of toxicophores and reactive metabolites* Chapter 9 (Prodrugs and Drug Delivery Systems): Discussion of antibody-drug conjugates.
(source: Nielsen Book Data)
Book
1 online resource.
A peptidomimetic is a small protein-like chain designed to mimic a peptide with adjusted molecular properties such as enhanced stability or biological activity. It is a very powerful approach for the generation of small-molecule-based drugs as enzyme inhibitors or receptor ligands. Peptidomimetics in Organic and Medicinal Chemistry outlines the concepts and synthetic strategies underlying the building of bioactive compounds of a peptidomimetic nature. Topics covered include the chemistry of unnatural amino acids, peptide- and scaffold-based peptidomimetics, amino acid-side chain isosteres, backbone isosteres, dipeptide isosteres, beta-turn peptidomimetics, proline-mimetics as turn inducers, cyclic scaffolds, amino acid surrogates, and scaffolds for combinatorial chemistry of peptidomimetics. Case studies in the hit-to-lead process, such as the development of integrin ligands and thrombin inhibitors, illustrate the successful application of peptidomimetics in drug discovery.
(source: Nielsen Book Data)
A peptidomimetic is a small protein-like chain designed to mimic a peptide with adjusted molecular properties such as enhanced stability or biological activity. It is a very powerful approach for the generation of small-molecule-based drugs as enzyme inhibitors or receptor ligands. Peptidomimetics in Organic and Medicinal Chemistry outlines the concepts and synthetic strategies underlying the building of bioactive compounds of a peptidomimetic nature. Topics covered include the chemistry of unnatural amino acids, peptide- and scaffold-based peptidomimetics, amino acid-side chain isosteres, backbone isosteres, dipeptide isosteres, beta-turn peptidomimetics, proline-mimetics as turn inducers, cyclic scaffolds, amino acid surrogates, and scaffolds for combinatorial chemistry of peptidomimetics. Case studies in the hit-to-lead process, such as the development of integrin ligands and thrombin inhibitors, illustrate the successful application of peptidomimetics in drug discovery.
(source: Nielsen Book Data)
Book
1 online resource (320 pages) : illustrations
  • Preface xiii Abbreviations xvii PART I The Basics of Peptidomimetics 1 1. The Basics of Peptidomimetics 3 1.1 Introduction 3 1.2 Definition and Classification 5 1.3 Strategic Approaches to Peptidomimetic Design 7 1.3.1 Modification of Amino Acids 8 1.3.2 Compounds with Global Restrictions 9 1.3.3 Molecular Scaffolds Mimicking the Peptidic Backbone 10 1.4 Successful Examples of Peptidomimetic Drugs 12 1.4.1 ACE Inhibitors 13 1.4.2 Thrombin Inhibitors 13 1.5 Conclusion 16 References 16 2. Synthetic Approaches towards Peptidomimetic Design19 2.1 Introduction 19 2.2 Local Modifications 20 2.2.1 Single Amino Acid Modifications 23 2.2.2 Dipeptide Isosteres 26 2.2.3 Retro-inverso Peptides 29 2.2.4 N-Methylation of Peptides 30 2.2.5 Azapeptides 31 2.2.6 Peptoids 31 2.3 Global Restrictions through Cyclic Peptidomimetics 32 2.4 Peptidomimetic Scaffolds 34 2.5 Conclusions 35 References 35 PART II Synthetic Methods and Molecules 37 3. Peptidomimetic Bioisosteres 39 3.1 Introduction 39 3.2 Peptide Bond Isosteres 40 3.2.1 Thioamides 41 3.2.2 Esters 41 3.2.3 Alkenes and Fluoroalkenes 41 3.2.4 Transition-State Isosteres 42 3.3 Side-Chain Isosteres 45 3.3.1 Guanidine Isosteres in Arginine Peptidomimetics 45 3.3.2 Isosteres of Aspartic Acid and Glutamic Acid 49 3.3.3 Tethered -Amino Acids: Constraining the -Space53 3.4 Dipeptide Isosteres 59 3.4.1 -Amino Acids 63 3.5 Tripeptide Isosteres 67 3.6 Conclusion 68 References 69 4. Solid-Phase Synthesis and Combinatorial Approaches toPeptidomimetics 75 4.1 Introduction 75 4.2 Solid-Phase Synthesis of Peptidomimetics 76 4.2.1 Scaffolds from -Amino Acids 76 4.2.2 Scaffolds from Amino Aldehyde Intermediates 85 4.2.3 Pyrrolidine-Containing Scaffolds 89 4.3 Conclusion 94 References 95 5. Click Chemistry: The Triazole Ring as a PrivilegedPeptidomimetic Scaffold 99 5.1 Introduction 99 5.1.1 CuAAC Reaction 100 5.1.2 Triazole Ring as a Peptidomimetic Isostere 101 5.2 Triazole-Containing Peptidomimetics Elaborated through Click Chemistry 102 5.2.1 Macrocycles 102 5.2.2 Oligomers and Foldamers 107 5.3 Relevant Applications in Drug Discovery 110 5.3.1 AChE Inhibitors 110 5.3.2 HIV Protease Inhibitors 111 5.3.3 MMP Inhibitors 114 5.3.4 Integrin Ligands 115 5.4 Conclusions 118 Acknowledgements 119 References 119 6. Peptoids 123 6.1 Introduction and Basics of Peptoids 123 6.2 Synthetic Methods 126 6.3 Macrocyclic Peptoids 129 6.4 Conformational Analysis of Folded Peptoids 130 6.5 Application of Peptoids as Antimicrobial Peptidomimetics132 6.6 Conclusions 134 References 134 7. Sugar Amino Acids 137 7.1 Introduction 137 7.2 -SAAs 138 7.2.1 Furanoid -SAAs 138 7.2.2 Pyranoid -SAAs 142 7.3 -SAAs 144 7.3.1 Furanoid -SAAs 144 7.3.2 Pyranoid -SAAs 147 7.4 -SAAs 148 7.5 -SAAs 150 7.5.1 Furanoid -SAAs 150 7.5.2 Pyranoid -SAAs 154 7.6 Representative Applications in Medicinal Chemistry 159 7.7 Conclusions 162 References 162 8. Cyclic -Amino Acids as Proline Mimetics 165 8.1 Introduction 165 8.2 Cyclic -Amino Acids 166 8.2.1 3-Substituted Proline Derivatives 167 8.2.2 4-Substituted Proline Derivatives 168 8.2.3 5-Substituted Proline Derivatives 169 8.2.4 Other Heterocyclic Proline Analogues 171 8.3 Bicyclic -Amino Acids 174 8.3.1 / -Ring Junction 175 8.3.2 / -Ring Junction 178 8.3.3 / -Ring Junction 179 8.3.4 / -Ring Junction 180 8.3.5 / -Ring Junction 182 8.3.6 N/ -Ring Junction 183 8.3.7 Pipecolic-Based Bicyclic -Amino Acids 183 8.3.8 Morpholine-Based Bicyclic -Amino Acids 187 8.4 Conclusions 189 References 189 9. -Turn Peptidomimetics 191 9.1 Introduction 191 9.2 Definition and Classification of -Turns 192 9.3 Conformational Analysis 194 9.4 -Turn Peptidomimetics 196 9.4.1 Proline Analogues in -Turn Peptidomimetics 197 9.4.2 -Amino Acids as Reverse-Turn Inducers 200 9.4.3 Molecular Scaffolds as -Turn Peptidomimetics 209 9.5 Conclusions 214 References 215 10. Peptidomimetic Foldamers 219 10.1 Introduction 219 10.2 Classification 220 10.3 Peptoids 221 10.4 -Peptides: First Systematic Conformational Studies221 10.5 Hybrid Foldamers 226 10.6 From Structural to Functional Foldamers 227 10.6.1 Peptoids as Foldameric Antimicrobial Peptidomimetics227 10.6.2 Foldamers Targeting Bcl-xL Antiapoptotic Proteins 227 10.7 Conclusions 228 References 228 PART III Applications in Medicinal Chemistry 231 11. Case Study 1: Peptidomimetic HIV Protease Inhibitors233 11.1 Introduction 233 11.2 The HIV-1 Virus 233 11.2.1 HIV-1 Protease 234 11.3 Antiretroviral Therapy 238 11.4 Drug Resistance 239 11.4.1 Mechanisms of Resistance to Protease Inhibitors 239 11.5 HIV-1 Protease Inhibitors 240 11.5.1 Transition-State Analogues 240 11.5.2 Peptidomimetic Drugs 241 11.5.3 Next-Generation Cyclic Peptidomimetic Inhibitors 245 11.6 Conclusions 255 Acknowledgements 255 References 256 12. Case Study 2: Peptidomimetic Ligands for Integrin259 12.1 Introduction 259 12.2 Peptide-Based Peptidomimetic Integrin Ligands 262 12.3 Scaffold-Based Peptidomimetic Integrin Ligands 270 12.4 Conclusions 280 References 280 Index 283.
  • (source: Nielsen Book Data)
A peptidomimetic is a small protein-like chain designed to mimic a peptide with adjusted molecular properties such as enhanced stability or biological activity. It is a very powerful approach for the generation of small-molecule-based drugs as enzyme inhibitors or receptor ligands. Peptidomimetics in Organic and Medicinal Chemistry outlines the concepts and synthetic strategies underlying the building of bioactive compounds of a peptidomimetic nature. Topics covered include the chemistry of unnatural amino acids, peptide- and scaffold-based peptidomimetics, amino acid-side chain isosteres, backbone isosteres, dipeptide isosteres, beta-turn peptidomimetics, proline-mimetics as turn inducers, cyclic scaffolds, amino acid surrogates, and scaffolds for combinatorial chemistry of peptidomimetics. Case studies in the hit-to-lead process, such as the development of integrin ligands and thrombin inhibitors, illustrate the successful application of peptidomimetics in drug discovery.
(source: Nielsen Book Data)
  • Preface xiii Abbreviations xvii PART I The Basics of Peptidomimetics 1 1. The Basics of Peptidomimetics 3 1.1 Introduction 3 1.2 Definition and Classification 5 1.3 Strategic Approaches to Peptidomimetic Design 7 1.3.1 Modification of Amino Acids 8 1.3.2 Compounds with Global Restrictions 9 1.3.3 Molecular Scaffolds Mimicking the Peptidic Backbone 10 1.4 Successful Examples of Peptidomimetic Drugs 12 1.4.1 ACE Inhibitors 13 1.4.2 Thrombin Inhibitors 13 1.5 Conclusion 16 References 16 2. Synthetic Approaches towards Peptidomimetic Design19 2.1 Introduction 19 2.2 Local Modifications 20 2.2.1 Single Amino Acid Modifications 23 2.2.2 Dipeptide Isosteres 26 2.2.3 Retro-inverso Peptides 29 2.2.4 N-Methylation of Peptides 30 2.2.5 Azapeptides 31 2.2.6 Peptoids 31 2.3 Global Restrictions through Cyclic Peptidomimetics 32 2.4 Peptidomimetic Scaffolds 34 2.5 Conclusions 35 References 35 PART II Synthetic Methods and Molecules 37 3. Peptidomimetic Bioisosteres 39 3.1 Introduction 39 3.2 Peptide Bond Isosteres 40 3.2.1 Thioamides 41 3.2.2 Esters 41 3.2.3 Alkenes and Fluoroalkenes 41 3.2.4 Transition-State Isosteres 42 3.3 Side-Chain Isosteres 45 3.3.1 Guanidine Isosteres in Arginine Peptidomimetics 45 3.3.2 Isosteres of Aspartic Acid and Glutamic Acid 49 3.3.3 Tethered -Amino Acids: Constraining the -Space53 3.4 Dipeptide Isosteres 59 3.4.1 -Amino Acids 63 3.5 Tripeptide Isosteres 67 3.6 Conclusion 68 References 69 4. Solid-Phase Synthesis and Combinatorial Approaches toPeptidomimetics 75 4.1 Introduction 75 4.2 Solid-Phase Synthesis of Peptidomimetics 76 4.2.1 Scaffolds from -Amino Acids 76 4.2.2 Scaffolds from Amino Aldehyde Intermediates 85 4.2.3 Pyrrolidine-Containing Scaffolds 89 4.3 Conclusion 94 References 95 5. Click Chemistry: The Triazole Ring as a PrivilegedPeptidomimetic Scaffold 99 5.1 Introduction 99 5.1.1 CuAAC Reaction 100 5.1.2 Triazole Ring as a Peptidomimetic Isostere 101 5.2 Triazole-Containing Peptidomimetics Elaborated through Click Chemistry 102 5.2.1 Macrocycles 102 5.2.2 Oligomers and Foldamers 107 5.3 Relevant Applications in Drug Discovery 110 5.3.1 AChE Inhibitors 110 5.3.2 HIV Protease Inhibitors 111 5.3.3 MMP Inhibitors 114 5.3.4 Integrin Ligands 115 5.4 Conclusions 118 Acknowledgements 119 References 119 6. Peptoids 123 6.1 Introduction and Basics of Peptoids 123 6.2 Synthetic Methods 126 6.3 Macrocyclic Peptoids 129 6.4 Conformational Analysis of Folded Peptoids 130 6.5 Application of Peptoids as Antimicrobial Peptidomimetics132 6.6 Conclusions 134 References 134 7. Sugar Amino Acids 137 7.1 Introduction 137 7.2 -SAAs 138 7.2.1 Furanoid -SAAs 138 7.2.2 Pyranoid -SAAs 142 7.3 -SAAs 144 7.3.1 Furanoid -SAAs 144 7.3.2 Pyranoid -SAAs 147 7.4 -SAAs 148 7.5 -SAAs 150 7.5.1 Furanoid -SAAs 150 7.5.2 Pyranoid -SAAs 154 7.6 Representative Applications in Medicinal Chemistry 159 7.7 Conclusions 162 References 162 8. Cyclic -Amino Acids as Proline Mimetics 165 8.1 Introduction 165 8.2 Cyclic -Amino Acids 166 8.2.1 3-Substituted Proline Derivatives 167 8.2.2 4-Substituted Proline Derivatives 168 8.2.3 5-Substituted Proline Derivatives 169 8.2.4 Other Heterocyclic Proline Analogues 171 8.3 Bicyclic -Amino Acids 174 8.3.1 / -Ring Junction 175 8.3.2 / -Ring Junction 178 8.3.3 / -Ring Junction 179 8.3.4 / -Ring Junction 180 8.3.5 / -Ring Junction 182 8.3.6 N/ -Ring Junction 183 8.3.7 Pipecolic-Based Bicyclic -Amino Acids 183 8.3.8 Morpholine-Based Bicyclic -Amino Acids 187 8.4 Conclusions 189 References 189 9. -Turn Peptidomimetics 191 9.1 Introduction 191 9.2 Definition and Classification of -Turns 192 9.3 Conformational Analysis 194 9.4 -Turn Peptidomimetics 196 9.4.1 Proline Analogues in -Turn Peptidomimetics 197 9.4.2 -Amino Acids as Reverse-Turn Inducers 200 9.4.3 Molecular Scaffolds as -Turn Peptidomimetics 209 9.5 Conclusions 214 References 215 10. Peptidomimetic Foldamers 219 10.1 Introduction 219 10.2 Classification 220 10.3 Peptoids 221 10.4 -Peptides: First Systematic Conformational Studies221 10.5 Hybrid Foldamers 226 10.6 From Structural to Functional Foldamers 227 10.6.1 Peptoids as Foldameric Antimicrobial Peptidomimetics227 10.6.2 Foldamers Targeting Bcl-xL Antiapoptotic Proteins 227 10.7 Conclusions 228 References 228 PART III Applications in Medicinal Chemistry 231 11. Case Study 1: Peptidomimetic HIV Protease Inhibitors233 11.1 Introduction 233 11.2 The HIV-1 Virus 233 11.2.1 HIV-1 Protease 234 11.3 Antiretroviral Therapy 238 11.4 Drug Resistance 239 11.4.1 Mechanisms of Resistance to Protease Inhibitors 239 11.5 HIV-1 Protease Inhibitors 240 11.5.1 Transition-State Analogues 240 11.5.2 Peptidomimetic Drugs 241 11.5.3 Next-Generation Cyclic Peptidomimetic Inhibitors 245 11.6 Conclusions 255 Acknowledgements 255 References 256 12. Case Study 2: Peptidomimetic Ligands for Integrin259 12.1 Introduction 259 12.2 Peptide-Based Peptidomimetic Integrin Ligands 262 12.3 Scaffold-Based Peptidomimetic Integrin Ligands 270 12.4 Conclusions 280 References 280 Index 283.
  • (source: Nielsen Book Data)
A peptidomimetic is a small protein-like chain designed to mimic a peptide with adjusted molecular properties such as enhanced stability or biological activity. It is a very powerful approach for the generation of small-molecule-based drugs as enzyme inhibitors or receptor ligands. Peptidomimetics in Organic and Medicinal Chemistry outlines the concepts and synthetic strategies underlying the building of bioactive compounds of a peptidomimetic nature. Topics covered include the chemistry of unnatural amino acids, peptide- and scaffold-based peptidomimetics, amino acid-side chain isosteres, backbone isosteres, dipeptide isosteres, beta-turn peptidomimetics, proline-mimetics as turn inducers, cyclic scaffolds, amino acid surrogates, and scaffolds for combinatorial chemistry of peptidomimetics. Case studies in the hit-to-lead process, such as the development of integrin ligands and thrombin inhibitors, illustrate the successful application of peptidomimetics in drug discovery.
(source: Nielsen Book Data)
Book
xiii, 715 pages : ill. (some color, chiefly tables) ; 26 cm.
  • From pharmacogenomics and systems biology to personalized care : a framework of systems and dynamical medicine / Qing Yan
  • Translational bioinformatics approaches for systems and dynamical medicine / Qing Yan
  • Whole blood transcriptomic analysis to identify clinical biomarkers of drug response / Grant P. Parnell and David R. Booth
  • Diagnostic procedures for paraffin-embedded tissues analysis in pharmacogenomic studies / Raffaele Palmirotta [and six others]
  • Approach to clinical and genetic characterization of statin-induced myopathy / QiPing Feng
  • Pharmacogenomics of membrane transporters : a review of current approaches / Tristan M. Sissung [and four others]
  • G protein-coupled receptor accessory proteins and signaling : pharmacogenomic insights / Miles D. Thompson [and three others]
  • G protein-coupled receptor mutations and human genetic disease / Miles D. Thompson [and four others]
  • Pharmacogenetics of the G protein-coupled receptors / Miles D. Thompson [and six others]
  • Pharmacogenomics of heart failure / Anastasios Lymperopoulos and Faren French
  • Pharmacogenomics in the development and characterization of atheroprotective drugs / Efi Valanti, Alexandros Tsompanidis, and Despina Sanoudou
  • Management of side effects in the personalized medicine era : chemotherapy-induced peripheral neuropathy / Paolo Alberti and G. Cavaletti
  • Pharmacogenomics of Alzheimer's disease : novel therapeutic strategies for drug development / Ramón Cacabelos [and four others]
  • Pharmacogenetics of antipsychotic treatment in schizophrenia / Jennie G. Pouget and Daniel J. Müller / Pharmacogenetics of addiction therapy / David A. Nielsen [and three others]
  • Pharmacogenetics in rheumatoid arthritis / Deepali Sen, Jisna R. Paul, and Prabha Ranganathan
  • Pharmacogenetics of osteoporotic fractures / José A. Riancho and Flor M. Pérez-Campo
  • Pharmacogenomics and pharmacoepigenomics in pediatric medicine / Barkur S. Shastry
  • Pharmacogenomics in children / Michael Rieder.
  • From pharmacogenomics and systems biology to personalized care : a framework of systems and dynamical medicine / Qing Yan
  • Translational bioinformatics approaches for systems and dynamical medicine / Qing Yan
  • Whole blood transcriptomic analysis to identify clinical biomarkers of drug response / Grant P. Parnell and David R. Booth
  • Diagnostic procedures for paraffin-embedded tissues analysis in pharmacogenomic studies / Raffaele Palmirotta [and six others]
  • Approach to clinical and genetic characterization of statin-induced myopathy / QiPing Feng
  • Pharmacogenomics of membrane transporters : a review of current approaches / Tristan M. Sissung [and four others]
  • G protein-coupled receptor accessory proteins and signaling : pharmacogenomic insights / Miles D. Thompson [and three others]
  • G protein-coupled receptor mutations and human genetic disease / Miles D. Thompson [and four others]
  • Pharmacogenetics of the G protein-coupled receptors / Miles D. Thompson [and six others]
  • Pharmacogenomics of heart failure / Anastasios Lymperopoulos and Faren French
  • Pharmacogenomics in the development and characterization of atheroprotective drugs / Efi Valanti, Alexandros Tsompanidis, and Despina Sanoudou
  • Management of side effects in the personalized medicine era : chemotherapy-induced peripheral neuropathy / Paolo Alberti and G. Cavaletti
  • Pharmacogenomics of Alzheimer's disease : novel therapeutic strategies for drug development / Ramón Cacabelos [and four others]
  • Pharmacogenetics of antipsychotic treatment in schizophrenia / Jennie G. Pouget and Daniel J. Müller / Pharmacogenetics of addiction therapy / David A. Nielsen [and three others]
  • Pharmacogenetics in rheumatoid arthritis / Deepali Sen, Jisna R. Paul, and Prabha Ranganathan
  • Pharmacogenetics of osteoporotic fractures / José A. Riancho and Flor M. Pérez-Campo
  • Pharmacogenomics and pharmacoepigenomics in pediatric medicine / Barkur S. Shastry
  • Pharmacogenomics in children / Michael Rieder.
Biology Library (Falconer)
Status of items at Biology Library (Falconer)
Biology Library (Falconer) Status
Stacks
QH506 .M45 V.1175 Unknown
Book
xii, 176 pages
  • Getting started
  • Discovery and preclinical work
  • Preparing for the clinic
  • Transferring technology
  • Commercialization and entrepreneurship
  • Concluding thoughts.
Written by the founders of the SPARK program at Stanford University, this book is a practical guide designed for professors, students and clinicians at academic research institutions who are interested in learning more about the drug development process and how to help their discoveries become the novel drugs of the future. Often many potentially transformative basic science discoveries are not pursued because they are deemed "too early" to attract industry interest. There are simple, relatively cost-effective things that academic researchers can do to advance their findings to the point that they can be tested in the clinic or attract more industry interest.
  • Getting started
  • Discovery and preclinical work
  • Preparing for the clinic
  • Transferring technology
  • Commercialization and entrepreneurship
  • Concluding thoughts.
Written by the founders of the SPARK program at Stanford University, this book is a practical guide designed for professors, students and clinicians at academic research institutions who are interested in learning more about the drug development process and how to help their discoveries become the novel drugs of the future. Often many potentially transformative basic science discoveries are not pursued because they are deemed "too early" to attract industry interest. There are simple, relatively cost-effective things that academic researchers can do to advance their findings to the point that they can be tested in the clinic or attract more industry interest.
Medical Library (Lane)
Status of items at Medical Library (Lane)
Medical Library (Lane) Status
Check Medical Library (Lane) catalog for status
RM301.25 .P733 2014 Unknown
Book
xii, 176 pages : illustrations.
Chemistry & ChemEng Library (Swain)
Status of items at Chemistry & ChemEng Library (Swain)
Chemistry & ChemEng Library (Swain) Status
Stacks
RM301.25 .P73 2014 Unknown
Book
1 online resource (xii, 394 pages) : illustrations (some color).
Book
online resource (xvi, 245 pages) : illustrations
  • Section I. A theory of evaluating drugs
  • section II. A theory of evidence in drug development
  • section III. Additional topics.
  • Section I. A theory of evaluating drugs
  • section II. A theory of evidence in drug development
  • section III. Additional topics.
Medical Library (Lane)
Status of items at Medical Library (Lane)
Medical Library (Lane) Status
Check Medical Library (Lane) catalog for status
CRCNETBASE Unknown

Looking for different results?

Modify your search: Remove limit(s) Search all fields

Search elsewhere: Search WorldCat Search library website